| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Biomerica, Inc.$2.02
+0.09 (+4.4%)
F 5Pipeline Score MedTech · Commercial
Market Cap
7.69 M
EPS
-1.50
P/E Ratio
-
Value Trade
21.27 K
SEC Financials
Q1 2026Dilution Risk
Revenue
987.00 K
R&D Expenses
178.00 K
Total Assets
4.88 M
Total Liabilities
1.56 M
Equity
3.32 M
D/E Ratio
12,345
2.89 %
Week
15.81 %
1 Month
12.67 %
3 Month
9.69 %
6 Month
-91.52 %
5 Year
-94.44 %
All Time
Cash Data
Cash Position
1.50 M
Monthly Burn
433.00 K
Runway
1.6 mo
Burn Trend
StableSEC Filing
Apr 13, 2026
Overview
Volume
24.79 K
52 Week Range
1.87 - 4.60
% held by Insiders
14.68 %
% held by Institutions
3.62 %
Enterprise Value
6.55 M
Total Shares
3.02 M
Short %
3.2 %
Float Shares
2.50 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
F5
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 5%
Micro Cap (rank 861 of 905)
Percentile RankBiomerica, Inc. has significant pipeline risk (5/100), but cash runway is a concern.
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
inFoods®IBS | Irritable Bowel Syndrome (IBS) | Phase 2 | 2025-06-27 | |||
inFoods®IBS | Irritable Bowel Syndrome (IBS) | Phase 2 | 2025-06-27 | |||
inFoods®IBS | Irritable Bowel Syndrome (IBS) | Phase 2 | 2025-06-27 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in BMRA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biomerica, Inc. (BMRA) Analyst Ratings & Price Targets
Symbol
Firm
Rating
Action
Price Target
Upside
date
BMRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BMRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BMRA
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
BMRA Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
BMRA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
BMRABiomerica Lands a $1.75 Million CDMO Master Services Agreement for IVD Diagnostic Development
Biomerica, Inc. has entered a Master Services Agreement worth $1.75 million with a confidential life sciences company for the development of IVD assays. The agreement will be executed over multiple Statements of Work and is set for an initial three-year term. This engagement allows Biomerica to utilize its established expertise in assay development while maintaining its focus on its primary product, inFoods® IBS.
Read more →BMRABiomerica Announces Medicare Administrative Contractor Confirmation of Individual Claim Review for inFoods® IBS, Opening a Scalable Medicare Commercialization Pathway
Biomerica has received confirmation from the Medicare Administrative Contractor that claims for its inFoods® IBS test will be reviewed on an individual basis, paving the way for Medicare coverage. The test, which identifies food triggers for IBS, is supported by strong clinical evidence and has a pre-established payment rate of $300. This development is expected to facilitate revenue generation for Biomerica starting January 1, 2026.
Read more →BMRABiomerica Reports Third Quarter Fiscal 2026 Financial Results
Biomerica, Inc. reported its third quarter fiscal 2026 financial results, highlighting positive real-world data for its inFoods®IBS product, which showed significant pain and bloating reduction in IBS patients. The company also announced a national Medicare payment rate for inFoods®IBS, enhancing patient access. Despite a decrease in net sales and an increase in net loss, European revenue grew by 45%, reflecting strong market demand.
Read more →BMRABiomerica Receives MHRA Registration for hp+detect™, Allowing Commercial Sales in Great Britain
Biomerica has received MHRA registration for its hp+detect™ diagnostic test, enabling commercial sales in Great Britain. This test detects H. pylori, a significant health concern linked to gastric cancer. The company is actively pursuing partnerships in the UK market to enhance access to this diagnostic tool. The registration marks a significant milestone for Biomerica's international expansion.
Read more →BMRABiomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
Biomerica, Inc. reported positive results from its real-world study of inFoods® IBS, showing that nearly 60% of patients experienced clinically meaningful reductions in abdominal pain and 68% achieved improvement in bloating. The study involved 69 patients and utilized FDA-recognized responder definitions, reinforcing the product's clinical utility. These findings are consistent with previous controlled trials, enhancing confidence in inFoods® IBS's effectiveness.
Read more →BMRAVietnam Approves Biomerica’s EZ Detect™ for Nationwide Distribution
Biomerica, Inc. has received approval from Vietnam's Hanoi Department of Health for its EZ Detect™ colorectal disease screening test. This at-home test aims to improve early detection of colorectal cancer, addressing a significant public health issue in Vietnam, where the survival rate for colorectal cancer is notably low. The company plans to collaborate with a major distributor to ensure widespread availability across various sales channels.
Read more →BMRABiomerica Reports Second Quarter Fiscal 2026 Financial Results
Biomerica reported its financial results for the second quarter of fiscal 2026, showing a decrease in net sales to $1.21 million compared to $1.64 million in the prior year. The company is transitioning to higher-margin diagnostic products, which has led to a strategic pivot affecting current revenues. Despite a net loss of $1.32 million, management remains optimistic about future growth driven by new product launches and partnerships.
Read more →BMRABiomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test
Biomerica has announced that the Centers for Medicare & Medicaid Services (CMS) set a national Medicare payment rate of $300 for its inFoods IBS test, effective January 1, 2026. This decision follows the approval of a unique CPT code for the test, enhancing patient access and commercial growth potential. The inFoods IBS test aims to address the unmet needs of IBS patients by identifying food triggers and providing targeted dietary recommendations.
Read more →BMRAEgyptian Drug Authority Authorizes Biomerica’s Complete Screening Test Portfolio
Biomerica, Inc. has received authorization from the Egyptian Drug Authority for its complete portfolio of rapid screening tests. This includes tests for colorectal, breast, and prostate cancers, as well as chronic diseases like kidney disease and H. pylori infection. The tests aim to facilitate early detection and are designed for easy use in various settings, addressing significant health needs in Egypt.
Read more →BMRABiomerica Expands Contract Development and Manufacturing Services to Meet Growing Market Demand
Biomerica, Inc. has announced the expansion of its Contract Development and Manufacturing Organization (CDMO) services to cater to increasing market demand. The company aims to enhance its capabilities, providing comprehensive support from concept to commercial manufacturing. With over 40 years of experience, Biomerica is well-positioned to assist diagnostic innovators while its updated website aims to improve partner engagement.
Read more →BMRAHenry Schein and Biomerica Enter into Marketing Services Agreement for Biomerica’s inFoods® IBS Test in the U.S.
Biomerica, Inc. has entered a marketing services agreement with Henry Schein, Inc. to promote its inFoods® IBS test across the U.S., excluding New York. This partnership aims to enhance the adoption of a non-drug therapy for IBS, leveraging Henry Schein's extensive distribution network. A recent clinical study published in Gastroenterology supports the test's efficacy, particularly for IBS-M patients.
Read more →BMRABiomerica Reports First Quarter Fiscal 2026 Financial Results
Biomerica, Inc. reported its financial results for the first quarter of fiscal 2026, revealing net sales of $1.4 million, a decrease from $1.8 million in the prior year. Despite lower sales, the company saw an increase in gross profit due to a favorable product mix. Operating expenses also decreased, leading to an improved operating loss of $1.1 million. Notably, Biomerica achieved a net profit of approximately $2,000, contrasting with a net loss of $1.3 million in the same quarter last year.
Read more →BMRAGary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
Biomerica Inc. has appointed Gary Huff, former CEO of LabCorp Diagnostics, to its Board of Directors. Huff's extensive experience in the diagnostics industry is expected to contribute to Biomerica's growth and innovation, particularly with its inFoods® IBS product aimed at improving patient care for irritable bowel syndrome. His strategic vision is anticipated to drive sustainable growth for the company.
Read more →BMRABiomerica Launches AI-Backed inFoods® IBS Trigger Food Navigator to Support Personalized IBS Therapy and Improve Patient Outcomes
Biomerica has launched the inFoods® IBS Trigger Food Navigator, an AI-driven tool designed to enhance dietary compliance for patients with Irritable Bowel Syndrome (IBS). This tool identifies specific food triggers and offers personalized meal suggestions, making it easier for patients to adhere to their dietary plans. Clinical studies have shown significant symptom relief, improving the quality of life for IBS patients.
Read more →BMRAUnited Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Kidney Test for Home Use
Biomerica, Inc. announced that the UAE Ministry of Health has approved its Fortel® Kidney Test for home use. This rapid test allows for the early detection of kidney damage, particularly beneficial for individuals with diabetes and hypertension. The approval aims to enhance healthcare access in the UAE, where these conditions are prevalent, and positions Biomerica as a leader in preventive diagnostics.
Read more →BMRAUnited Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Home Use
Biomerica, Inc. has received approval from the UAE Ministry of Health for its Fortel® Ulcer Test, allowing for home use. This rapid diagnostic test detects H. pylori, a major cause of gastric diseases. With approximately 41% of the UAE population affected, the test aims to facilitate early detection and treatment, potentially reducing serious complications associated with the infection.
Read more →BMRAInFoods IBS receives CPT® Proprietary Laboratory Analysis (PLA) Code
Biomerica, Inc. announced that the American Medical Association has issued a CPT code for its inFoods IBS test, effective October 1, 2025. This code will facilitate insurance claims and enhance patient access to the test, which identifies food triggers for IBS symptoms. The test has shown significant clinical effectiveness in trials, supporting its commercialization strategy.
Read more →BMRAClinical Diagnostics Industry Leader Scott Madel Joins Biomerica’s Team as Chief Commercial Officer
Biomerica Inc. has appointed Scott Madel as Chief Commercial Officer to enhance the commercialization of its inFoods®IBS product. With extensive experience in healthcare and diagnostics, Madel aims to drive revenue growth and expand strategic partnerships. The inFoods®IBS test is designed to identify food triggers for IBS symptoms, offering a precision-based approach to treatment.
Read more →Competitive Position
How BMRA ranks across every disease it competes inCompetitive Position is a premium feature
See how BMRA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial